Advertisement

Drug–Nutrient Interactions

  • Srinivas Guptha Gunturu
  • T. S. Dharmarajan
  • T. S. Dharmarajan
  • T. S. Dharmarajan
  • T. S. Dharmarajan
Chapter

Abstract

Drug–nutrient interactions (DNIs) are on the increase in older adults due to high prevalence of polypharmacy, which presents an opportunity for drug interactions with nutrients. The impact and burden of DNIs in older adults are many, including morbidity, hospitalizations, and mortality. DNIs are contributary to adverse drug events. DNIs occur among a wide range of therapeutic classes. The risk factors contributing to DNIs, types of interactions, consequences, and examples of commonly used medications and herbal preparations and their interactions with nutrients are presented. Awareness of DNIs and proper drug selection offers opportunity for diagnosis and prevention.

Keywords

Grape Seed Extract Cranberry Juice Hepatic Extraction Ratio Enteral Tube Feeding Hepatic Drug Clearance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Chan LN. Drug nutrient interactions in clinical nutrition. Curr Opin Clin Nutr Metab Care. 2002;5:327–32.PubMedCrossRefGoogle Scholar
  2. 2.
    Lourenco R. Enteral feeding: drug/nutrient interaction. Clin Nutr. 2001;20(2):187–93.PubMedCrossRefGoogle Scholar
  3. 3.
    Chan LN. Drug-nutrient interactions in transplant recipients. J Parenter Enteral Nutr. 2001;25(3):132–41.CrossRefGoogle Scholar
  4. 4.
    Ward LS. The difficult patient: drug interactions and the influence of concomitant diseases on the treatment of hypothyroidism. Arq Bras Endocrinol Metabol. 2010;54(5):435–42.PubMedCrossRefGoogle Scholar
  5. 5.
    Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49(8):509–33.PubMedCrossRefGoogle Scholar
  6. 6.
    Hata M, Hayasaka M, Sezai A, et al. Proton pump inhibitors may increase the risk of delayed bleeding complications after open heart surgery if used concomitantly with warfarin. Thorac Cardiovasc Surg. 2008;56(05):274–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther. 2010;31(11):1165–77.PubMedCrossRefGoogle Scholar
  8. 8.
    Zarowitz BJ. Pharmacologic consideration of commonly used gastrointestinal drugs in the elderly. Gastroenterol Clin North Am. 2009;38(3):547–62.PubMedCrossRefGoogle Scholar
  9. 9.
    Dharmarajan TS, Kanagala MR, Murakonda P, Lebelt AS, Norkus EP. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc. 2008;9(3):162–7.PubMedCrossRefGoogle Scholar
  10. 10.
  11. 11.
    McLean AJ. Aging biology and geriatric clinical pharmacology. Pharmacol Rev. 2004;56(2):163–84.PubMedCrossRefGoogle Scholar
  12. 12.
    McCabe BJ. Prevention of food-drug interactions with special emphasis on older adults. Curr Opin Clin Nutr Metab Care. 2004;7:21–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. 2007;370(9582):185–91.PubMedCrossRefGoogle Scholar
  14. 14.
    Utermohlen V. Nutrient–drug interactions. Encyclopedia of Food and Culture. 2003. http://www.encyclopedia.com/doc/1G2-3403400440.html. Accessed 23 Jan 2011.
  15. 15.
    Sorenson JM. Herb-drug, food-drug, nutrient-drug and drug-drug interactions: mechanisms involved and their medical implications. J Altern Complement Med. 2002;8(3):293–308.CrossRefGoogle Scholar
  16. 16.
    Dharmarajan TS, Pitchumoni CS, Kokkat AJ. The aging gut. Pract Gastroenterol. 2001;25:15–27.Google Scholar
  17. 17.
    Akamine D, Filho MK, Peres CM. Drug nutrient interactions in elderly people. Curr Opin Clin Nutr Metab Care. 2007;10:304–10.PubMedCrossRefGoogle Scholar
  18. 18.
    Armbrecht HJ, Boltz MA, Kumar VB. Intestinal plasma membrane calcium pump protein and its induction by 1,25 (OH)2D3 decrease with age. Am J Physiol Gastrointest Liver Physiol. 1999;277:G41–7.Google Scholar
  19. 19.
    Toyoshima M, Inada M, Kameyama M. Effects of aging on intracellular transport of vitamin B12 (B12) in rat enterocytes. J Nutr Sci Vitaminol (Tokyo). 1983;29(1):1–10.CrossRefGoogle Scholar
  20. 20.
    Custodio J, Wu C, Benet L. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008;60(6):717–33.PubMedCrossRefGoogle Scholar
  21. 21.
    Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol. 2003;38(8):843–53.PubMedCrossRefGoogle Scholar
  22. 22.
    Genser D. Food and drug interaction: consequences for the nutrition/health status. Ann Nutr Metab. 2008;52(1):29–32.PubMedCrossRefGoogle Scholar
  23. 23.
    Alemdaroglu NC, Dietz U, Wolffram S, Spahn-Langguth H, Langguth P. Influence of green and black tea on folic acid pharmacokinetics in healthy volunteers: potential risk of diminished folic acid bioavailability. Biopharm Drug Dispos. 2008;29(6):335–48.PubMedCrossRefGoogle Scholar
  24. 24.
    Simon Z. The effect of milk components, especially of casein, on the bioavailability of ciprofloxacin tablets cannot be evaluated by dissolution testing. J Pharm Biomed Anal. 2010;53(3):819.PubMedCrossRefGoogle Scholar
  25. 25.
    De Lemos ML, Hamata L, Jennings S, Leduc T. Interaction between mercaptopurine and milk. J Oncol Pharm Pract. 2007;13(4):237–40.PubMedCrossRefGoogle Scholar
  26. 26.
    Mulligan GB, Licata A. Taking vitamin D with the largest meal improves absorption and results in higher serum levels of 25-hydroxyvitamin D. J Bone Miner Res. 2010;25(4):928–30.PubMedCrossRefGoogle Scholar
  27. 27.
    Schmidt LE, Dalhoff K. Food-drug interactions. Drugs. 2002;62(10):1481–502.PubMedCrossRefGoogle Scholar
  28. 28.
    Gauthier I, Malone M. Drug-food interactions in hospitalised patients. Methods of prevention. Drug Saf. 1998;18(6):383–93.PubMedCrossRefGoogle Scholar
  29. 29.
    Lee RD, Vakily M, Mulford D, Wu J, Atkinson SN. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor–evidence for dosing flexibility. Aliment Pharmacol Ther. 2009;29(8):824–33.PubMedCrossRefGoogle Scholar
  30. 30.
    Gregory C. Drug and enteral feed interactions. J Hum Nutr Diet. 2006;19(3):237–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Kim T-E, Kim B-H, Kim J-R, et al. Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol. 2009;68(1):43–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Khosravan R, Grabowski B, Wu J-T, Joseph-Ridge N, Vernillet L. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. Br J Clin Pharmacol. 2008;65(3):355–63.PubMedCrossRefGoogle Scholar
  33. 33.
    Fernandez R, Phillips SF. Components of fiber bind iron in vitro. Am J Clin Nutr. 1982;35(1):100–6.PubMedGoogle Scholar
  34. 34.
    Floren CH, Nilsson A. Binding of bile salts to fibre-enriched wheat fibre. Scand J Gastroenterol Suppl. 1987;129:192–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Heaney RP, Weaver CM. Effect of psyllium on absorption of co-ingested calcium. J Am Geriatr Soc. 1995;43(3):261–3.PubMedGoogle Scholar
  36. 36.
    Lentz KA. Current methods for predicting human food effect. AAPS J. 2008;10(2):282–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Pelton R, LaValle JB, Hawkins EB, Krinsky DL. Drug-induced nutrient depletion handbook: 1999–2000. Hudson: Lexi-comp; 1999.Google Scholar
  38. 38.
    Mason P. Important drug–nutrient interactions. Proc Nutr Soc. 2010;69(04):551–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Henley E. Sorbitol-based elixirs, diarrhea and enteral tube feeding. Am Fam Physician. 1997;55(6):2084; 2086.Google Scholar
  40. 40.
    Abad MJ, Bedoya LM, Bermejo P. An update on drug interactions with the herbal medicine Ginkgo biloba. Curr Drug Metab. 2010;11(2):171–81.PubMedCrossRefGoogle Scholar
  41. 41.
    Bressler R. Herb-drug interactions: interactions between ginseng and prescription medications. Geriatrics. 2005;60(8):16–7.PubMedGoogle Scholar
  42. 42.
    Bressler R. Herb-drug interactions. Interactions between saw palmetto and prescription medications. Geriatrics. 2005;60(11):32; 34.Google Scholar
  43. 43.
    Wittkowsky AK. Dietary supplements, herbs and oral anticoagulants: the nature of the evidence. J Thromb Thrombolysis. 2008;25(1):72–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Ansell J, McDonough M, Zhao Y, Harmatz JS, Greenblatt DJ. The absence of an interaction between warfarin and cranberry juice: a randomized, double-blind trial. J Clin Pharmacol. 2009;49(7):824–30.PubMedCrossRefGoogle Scholar
  45. 45.
    Hamann GL, Campbell JD, George CM. Warfarin-cranberry juice interaction. Ann Pharmacother. 2011;45(3):e17.PubMedCrossRefGoogle Scholar
  46. 46.
    Dharmarajan L, Dharmarajan TS. Prescribing warfarin appropriately to meet Patient Safety Goals. Am Health Drug Benefits. 2008;1(6):26–32.Google Scholar
  47. 47.
    Moore AA, Blow FC, Hoffing M, et al. Primary care-based intervention to reduce at-risk drinking in older adults: a randomized controlled trial. Addiction. 2011;106(1):111–20.PubMedCrossRefGoogle Scholar
  48. 48.
    Hamid A, Kaur J. Long-term alcohol ingestion alters the folate-binding kinetics in intestinal brush border membrane in experimental alcoholism. Alcohol. 2007;41(6):441–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Hamid A, Wani NA, Kaur J. New perspectives on folate transport in relation to alcoholism-induced folate malabsorption - association with epigenome stability and cancer development. FEBS J. 2009;276(8):2175–91.PubMedCrossRefGoogle Scholar
  50. 50.
    Gilbert RM. Caffeine consumption. Prog Clin Biol Res. 1984;158:185–213.PubMedGoogle Scholar
  51. 51.
    Nehlig A. Are we dependent upon coffee and caffeine a review on human and animal data. Neurosci Biobehav Rev. 1999;23:563–76.PubMedCrossRefGoogle Scholar
  52. 52.
    Rapuri P, Gallagher J, Nawaz Z. Caffeine decreases vitamin D receptor protein expression and 1,25(OH)2D3 stimulated alkaline phosphatase activity in human osteoblast cells. J Steroid Biochem Mol Biol. 2007;103(3–5):368–71.PubMedCrossRefGoogle Scholar
  53. 53.
    Korpelainen R, Korpelainen J, Heikkinen J, et al. Lifestyle factors are associated with osteoporosis in lean women but not in normal and overweight women: a population-based cohort study of 1222 women. Osteoporos Int. 2003;14(1):34–43.PubMedCrossRefGoogle Scholar
  54. 54.
    Hallström H, Wolk A, Glynn A, Michaëlsson K. Coffee, tea and caffeine consumption in relation to osteoporotic fracture risk in a cohort of Swedish women. Osteoporos Int. 2006;17(7):1055–64.PubMedCrossRefGoogle Scholar
  55. 55.
    Eadie MJ. Clinically significant drug interactions with agents specific for migraine attacks. CNS Drugs. 2001;15(2):105–18.PubMedCrossRefGoogle Scholar
  56. 56.
    Jankiewicz K, Chroscinska-Krawczyk M, Blaszczyk B, Czuczwar SJ. Caffeine and antiepileptic drugs: experimental and clinical data. Przegl Lek. 2007;64(11):965–7.PubMedGoogle Scholar
  57. 57.
    Cysneiros RM, Farkas D, Harmatz JS, von Moltke LL, Greenblatt DJ. Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine. Clin Pharmacol Ther. 2007;82(1):54–62.PubMedCrossRefGoogle Scholar
  58. 58.
    Hegarty VM, May HM, Khaw K. Tea drinking and bone mineral density in older women. Am J Clin Nutr. 2000;71:1003–7.PubMedGoogle Scholar
  59. 59.
    Chen Z. Habitual tea consumption and risk of osteoporosis: a prospective study in the women’s health initiative observational cohort. Am J Epidemiol. 2003;158(8):772–81.PubMedCrossRefGoogle Scholar
  60. 60.
    Devine A, Hodgson JM, Dick IM, Prince RL. Tea drinking is associated with benefits on bone density in older women. Am J Clin Nutr. 2007;86:1243–7.PubMedGoogle Scholar
  61. 61.
    Cooper M, Safran M, Eberhardt M. Caffeine consumption among adults on benzodiazepine therapy: United States 1988–1994. Psychol Rep. 2004;95(1):183–91.PubMedCrossRefGoogle Scholar
  62. 62.
    Houston MC. Nutrition and nutraceutical supplements in the treatment of hypertension. Expert Rev Cardiovasc Ther. 2010;8(6):821–33.PubMedCrossRefGoogle Scholar
  63. 63.
    Brosen K. Differences in interactions of SSRIs. Int Clin Psychopharmacol. 1998;13 Suppl 5:S45–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Nathisuwan S, Dilokthornsakul P, Chaiyakunapruk N, et al. Assessing evidence of interaction between smoking and warfarin: a systematic review and meta-analysis. Chest. 2011;139(5):1130–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet. 1999;36(6):425–38.PubMedCrossRefGoogle Scholar
  66. 66.
    Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm. 2007;64(18):1917–21.PubMedCrossRefGoogle Scholar
  67. 67.
    Vitamin D. 2010. http://www.nlm.nih.gov/medlineplus/druginfo/natural/929.html. Accessed 27 Jan 2011.
  68. 68.
    Dharmarajan TS, Norkus EP. Does long-term PPI use result in vitamin B12 deficiency in elderly individuals? Nat Clin Pract Gastroenterol Hepatol. 2008;5(11):604–5.PubMedCrossRefGoogle Scholar
  69. 69.
    Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010;12(6):448–57.PubMedCrossRefGoogle Scholar
  70. 70.
    Stover PJ. Vitamin B12 and older adults. Curr Opin Clin Nutr Metab Care. 2010;13(1):24–7.PubMedCrossRefGoogle Scholar
  71. 71.
    Liu KW. Metformin-related vitamin B12 deficiency. Age Ageing. 2006;35(2):200–1.PubMedCrossRefGoogle Scholar
  72. 72.
    Ezra A, Hoffman A, Breuer E, et al. A peptide prodrug approach for improving bisphosphonate oral absorption. J Med Chem. 2000;43:3641–52.PubMedCrossRefGoogle Scholar
  73. 73.
    Mitchell DY, Eusebio RA, Sacco-Gibson NA. Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. J Clin Pharmacol. 2000;40(3):258–65.PubMedCrossRefGoogle Scholar
  74. 74.
    Gertz BJ, Holland SD, Kline WF. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther. 1995;58(3):288–98.PubMedCrossRefGoogle Scholar
  75. 75.
    Umland EM, Boyce EG. Risedronate a new oral bisphosphonate. Clin Ther. 2001;24(5):835–6.Google Scholar
  76. 76.
    Williams NT. Medication administration through enteral feeding tubes. Am J Health Syst Pharm. 2008;65(24):2347–57.PubMedCrossRefGoogle Scholar
  77. 77.
    Beckwith MC, Feddema SS, Barton RG, Graves C. A guide to drug therapy in patients with enteral feeding tubes: dosage form selection and administration methods. Hosp Pharm. 2004;39(3):225–37.Google Scholar
  78. 78.
    Brown RO, Dickerson RN. Drug nutrient interactions. Am J Manag Care. 2000;5(3):345–55.Google Scholar
  79. 79.
    Klang M, Graham D, McLymont V. Warfarin bioavailability with feeding tubes and enteral formula. J Parenter Enteral Nutr. 2010;34(3):300–4.CrossRefGoogle Scholar
  80. 80.
    Muramatsu RS, Litzinger MHJ, Fisher E, Takeshita J. Alternative formulations, delivery methods, and administration options for psychotropic medications in elderly patients with behavioral and psychological symptoms of dementia. Am J Geriatr Pharmacother. 2010;8(2):98–114.PubMedCrossRefGoogle Scholar
  81. 81.
    Wohlt PD, Zheng L, Gunderson S, et al. Recommendations for the use of medications with continuous enteral nutrition. Am J Health Syst Pharm. 2009;66(16):1458–67.PubMedCrossRefGoogle Scholar
  82. 82.
    Mirtallo JM. Complications associated with drug and nutrient interactions. J Infus Nurs. 2004;27(1):19–24.PubMedCrossRefGoogle Scholar
  83. 83.
    Gardiner P, Graham R, Legedza ATR, et al. Factors associated with herbal therapy use by adults in the USA. Altern Ther Health Med. 2007;13:22–9.PubMedGoogle Scholar
  84. 84.
    Bent S. Commonly used herbal medicines in the United States: a review. Am J Med. 2004;116(7):478–85.PubMedCrossRefGoogle Scholar
  85. 85.
    Nowack R. Cytochrome P450 enzyme, and transport protein mediated herb–drug interactions in renal transplant patients: grapefruit juice, St John’s wort—and beyond! (review article). Nephrology. 2008;13(4):337–47.PubMedCrossRefGoogle Scholar
  86. 86.
    Boobis A, Watelet J-B, Whomsley R, et al. Drug interactions. Drug Metab Rev. 2009;41(3):486–527.PubMedCrossRefGoogle Scholar
  87. 87.
    Sica D. Interaction of grapefruit juice and calcium channel blockers. Am J Hypertens. 2006;19(7):768–73.PubMedCrossRefGoogle Scholar
  88. 88.
    Dharmarajan TS, Pitchumoni CS. Drug-nutrient interactions in older adults. Pract Gastroenterol. 2002;26(4):37–55.Google Scholar
  89. 89.
    Tapaninen T, Neuvonen PJ, Niemi M. Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren. Clin Pharmacol Ther. 2010;88(3):339–42.PubMedCrossRefGoogle Scholar
  90. 90.
    Lin C, Ke X, Ranade V, Somberg J. The additive effects of the active component of grapefruit juice (naringenin) and antiarrhythmic drugs on HERG inhibition. Cardiology. 2008;110(3):145–52.PubMedCrossRefGoogle Scholar
  91. 91.
    Hammerness P, Basch E, Ulbricht C, et al. St John’s wort a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics. 2003;44:271–82.PubMedCrossRefGoogle Scholar
  92. 92.
    Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John’s wort (hypericum perforatum) drug interactions and clinical outcomes. Br J Clin Pharmacol. 2002;54:349–56.PubMedCrossRefGoogle Scholar
  93. 93.
    Han H-K. The effects of black pepper on the intestinal absorption and hepatic metabolism of drugs. Expert Opin Drug Metab Toxicol. 2011;7(6):721–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John’s wort, ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med. 2002;136:42–53.PubMedGoogle Scholar
  95. 95.
    Sanchez-Muniz FJ, Bastida S, Gutierrez-Garcia O, Carbajal A. Olive oil-diet improves the simvastatin effects with respect to sunflower oil-diet in men with increased cardiovascular risk: a preliminary study. Nutr Hosp. 2009;24(3):333–9.PubMedGoogle Scholar
  96. 96.
    Ovesen L, Lyduch S, Idorn ML. The effect of a diet rich in brussels sprouts on warfarin pharmacokinetics. Eur J Clin Pharmacol. 1988;33:521–3.CrossRefGoogle Scholar
  97. 97.
    Deferme S, Mols R, Van Driessche W, Augustijns P. Apricot extract inhibits the P-gp-mediated efflux of talinolol. J Pharm Sci. 2002;91(12):2539–48.PubMedCrossRefGoogle Scholar
  98. 98.
    Al-Ghazawi MA, Tutunji MS, AbuRuz SM. The effects of pummelo juice on pharmacokinetics of sildenafil in healthy adult male Jordanian volunteers. Eur J Clin Pharmacol. 2010;66(2):159–63.PubMedCrossRefGoogle Scholar
  99. 99.
    Houston MC. The role of cellular micronutrient analysis, nutraceuticals, vitamins, antioxidants and minerals in the prevention and treatment of hypertension and cardiovascular disease. Ther Adv Cardiovasc Dis. 2010;4(3):165–83.PubMedCrossRefGoogle Scholar
  100. 100.
    Pae C, Lim H, Han C, Neena A, Lee C, Patkar A. Selegiline transdermal system: current awareness and promise. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1153–63.PubMedCrossRefGoogle Scholar
  101. 101.
    Bush TM, Rayburn KS, HoUoway SW, et al. Adverse interactions between herbal and dietary substances and prescription medications a clinical survey. Altern Ther Health Med. 2007;13(2):30–5.PubMedGoogle Scholar
  102. 102.
    Vaes LPJ, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother. 2000;34:1478–82.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Srinivas Guptha Gunturu
    • 1
  • T. S. Dharmarajan
    • 2
  • T. S. Dharmarajan
    • 3
  • T. S. Dharmarajan
    • 4
  • T. S. Dharmarajan
    • 5
  1. 1.Department of MedicineMontefiore Medical Center (North Division)BronxUSA
  2. 2.New York Medical CollegeValhallaUSA
  3. 3.Department of MedicineMontefiore Medical Center (North Division)BronxUSA
  4. 4.Division of GeriatricsMontefiore Medical Center (North Division)BronxUSA
  5. 5.Geriatric Medicine Fellowship ProgramMontefiore Medical Center (North Division)BronxUSA

Personalised recommendations